-
Most Recent
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
China’s Diabetes Epidemic Boosts Big Pharma
The world's largest population of diabetics is growing alarmingly, and combating it raises the prospects for names like Merck, Novo Nordisk and Sanofi.
Novartis Flu Vaccine Ban: Who Wins?
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why.
Biotechs Beat Q3 Earnings, Revenue Estimates
Amgen, Gilead Science and Questcor Pharmaceuticals posted third-quarter earnings and revenue that beat Wall Street forecasts.
Bristol-Myers, Eli Lilly Miss Q3 Forecasts, Shares Slide
Bristol-Myers Squibb and Eli Lilly reported third-quarter earnings that missed Wall Street estimates as generic competition slammed drug sales.
Should I Buy Abbott Labs? 3 Pros, 3 Cons
Success in a drug regimen meant to treat hepatitis C is buoying shares of Abbott Laboratories, but has the easy money in ABT shares already been made?
FDA Pulls Approval for a Generic Antidepressant
A generic version of antidepressant Wellbutrin has lost FDA approval after tests showed it less effective than the brand name drug at a certain dosage.
Woman’s $180 Stock Buy Balloons to $7M
Sometimes buy and hold REALLY does pay off. The late Grace Groner's purchase of three Abbott Labs shares in 1935 worked out well.
10 Hottest Small-Cap Stocks of 2012
These 10 small to midsize businesses have seen returns ranging from 210 to 670% in just nine months. See which sector makes up most of this high-flying crowd.
A Healthy Portfolio Is Heavy in Health Care
Investors would be foolish to ignore the massive demographic shift and growth potential that is boosting health care stocks right now.
Are You Missing the Biotech Boat?
Biotech stocks have been one of the market's best performing areas during the past year and beyond. Is it too late to catch this comet?
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
Monsanto’s Genetically Modified Corn Losing Effectiveness
The Environmental Protection Agency says that a number of studies show that rootworms are developing resistance to Monsanto's genetically modified corn.
Believe In This M&A Mastermind
Including its Medicis deal, Valeant Pharmaceuticals has made 27 acquisitions in the past four-plus years -- and it's showing no signs of capsizing.
Bet on Biotech With ViroPharma
Biotech stocks are speculative picks. But if you're willing to take a risk, ViroPharma is the way to go.
Gilead Poised to Go From Good to Great?
Gilead faces a pivotal FDA decision on its HIV "quad" pill Monday. Even if it's not much better than what's available, approval would be good news for investors.
Banking on Buyouts in Biotech: Is It Smart?
Unless you really understand medicine, it's a very risky game. The chances of a little company scoring big and getting bought out are usually slim.
Cracked Wood in Market Resistance Zone Spells Trouble
Markets may be getting ahead of themselves at this point, and savvy investors may want to revisit some portfolio names that have run up, including these pharmas
Israel: Beyond the Risk, Opportunities Beckon
When you think of Israel, you probably think of conflict. But it has a strong economy and growing companies if you're willing to be a bit daring.
